[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-367564-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-367564-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","identification-of-dcaf5-as-a-novel-cancer-prognostic-and-immunotherapy-biomarker-through-pan-cancer-analysis-and-renal-clear-cell-carcinoma-clinical-data-validation","Identification of DCAF5 as a novel cancer prognostic and immunotherapy biomarker through pan-cancer analysis and renal clear cell carcinoma clinical data validation","","DCAF5 encodes a ubiquitin ligase complex component and is implicated in protein ubiquitination, with emerging evidence suggesting roles in reversing malignant phenotypes, yet limited development-focused research remains. Using immunohistochemistry, DCAF5 expression was compared between renal clear cell carcinoma and adjacent non-neoplastic tissues, followed by survival analyses tied to patient outcomes. Public databases (UCSC Xena, TCGA, and GTEx) were analyzed to characterize expression heterogeneity and relationships with immune activity and infiltration, and genetic alterations were assessed. DCAF5 showed reduced expression in tumors, correlated with immune features and prognosis, and showed predictive performance beyond TMB, supporting its dual biomarker potential for immunotherapy.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/identification-of-dcaf5-as-a-novel-cancer-prognostic-and-immunotherapy-biomarker-through-pan-cancer-analysis-and-renal-clear-cell-carcinoma-clinical-data-validation/367564/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/identification-of-dcaf5-as-a-novel-cancer-prognostic-and-immunotherapy-biomarker-through-pan-cancer-analysis-and-renal-clear-cell-carcinoma-clinical-data-validation/367564.png","ImageObject",300,407,{"name":42,"@type":43},"Melati","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-02","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What role does DCAF5 play in cancer biology according to the study?","Question",{"text":63,"@type":64},"DCAF5 encodes a component of a ubiquitin ligase complex that influences protein ubiquitination. The paper notes prior evidence linking it to potential reversal of malignant phenotypes, while highlighting limited research for development as a cancer target.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How was DCAF5 expression measured in renal clear cell carcinoma?",{"text":68,"@type":64},"The study used immunohistochemical analysis to compare DCAF5 expression in renal clear cell carcinoma tissues with adjacent non-neoplastic tissues.",{"name":70,"@type":61,"acceptedAnswer":71},"What did the study find about DCAF5 as a prognostic and immunotherapy biomarker?",{"text":72,"@type":64},"DCAF5 expression was significantly reduced in tumor tissues, associated with patient outcomes, and correlated with immune scores and immune cell infiltration across multiple cancer types. The findings indicate superior predictive value over traditional biomarkers such as TMB for immunotherapy personalization.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},367564,1790887466,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":127,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":33,"preview_urls":145},962085570644,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","Yan et al. Discover Oncology (2025) 16:1119 [https://doi.org/10.1007/s12672-025-02974-6](https://doi.org/10.1007/s12672-025-02974-6)  \nDiscover Oncology  \nRESEARCH Open Access  \nIdentification of DCAF5 as a novel cancer  \nprognostic and immunotherapy biomarker through pan-cancer analysis and renal clear cell carcinoma clinical data validation  \nHuaqing Yan 1*, Liqi Zhang2, Fan Xu 1, Tieding Chen 1 and Rubing Li 1*  \n*Correspondence: Huaqing Yan [yanhuaqing@zju.edu.cn](yanhuaqing@zju.edu.cn)[ ](yanhuaqing@zju.edu.cn)Rubing Li[lhluro@163.com](lhluro@163.com)  \n1Department of Urology, Ningbo Medical Center Lihuili Hospital, Ningbo 315000, Zhejiang, People’s Republic of China  \n2Department of Reproductive Medicine, The First Affiliated Hospital of Ningbo University, Ningbo 315000, Zhejiang, People’s Republic of China  \nAbstract  \nBackground DCAF5 encodes a component of ubiquitin ligase complex, thereby influencing protein ubiquitination. Recent research underscored its potential to revert the malignant phenotype, as evidenced in vivo studies, while the scarcity of research about DCAF5 challenges for its development as a novel target for cancer treatment. Methods We conducted an immunohistochemical analysis to compare the expression levels of DCAF5 in renal clear cell carcinoma tissues with those in adjacent non-neoplastic tissues. Subsequently, we performed survival analyses to explore the correlation between DCAF5 expression and patient outcomes. Multiple public databases were used such as the UCSC Xena platform, The Cancer Genome Atlas, and the Genotype-Tissue Expression project. The raw data extracted from the UCSC Xena platform was subsequently processed utilizing online analytical tools to facilitate further in-depth examination.  \nResults Our investigation has discovered a significant reduction in DCAF5 expression within renal clear cell carcinoma tissues when juxtaposed with adjacent non-cancerous tissues. Further experimental validation demonstrated that patients with higher pathology grades exhibited lower DCAF5 expression. In a broader oncological context, our comprehensive analysis across various cancer types revealed a heterogeneous expression pattern of DCAF5 . Concurrently, an examination of publicly accessible databases has highlighted a notable correlation between DCAF5 expression and both immune scores and immune cell infiltration in a range of cancer types. It is noteworthy that DCAF5 ‘s potential as an immunotherapy biomarker was recognized, distinguishing it from several established markers in this domain. Finally, our analysis of genetic alterations identified gene amplification as the predominant form of aberration affecting the DCAF5 gene.  \nConclusion Our findings reveal that DCAF5 exhibits context-dependent dual roles across cancers and demonstrates superior predictive value over traditional biomarkers like TMB in immunotherapy. This highlights its potential as a dual-functional biomarker  \n© The Author(s) 2025. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/l](http://cre","cbCaigTuWIhJMsvD","https://ap.wps.com/l/cbCaigTuWIhJMsvD","pdf",3630695,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusion\n# Keywords\n# 1 Introduction","[{\"question\":\"What role does DCAF5 play in cancer biology according to the study?\",\"answer\":\"DCAF5 encodes a component of a ubiquitin ligase complex that influences protein ubiquitination. The paper notes prior evidence linking it to potential reversal of malignant phenotypes, while highlighting limited research for development as a cancer target.\"},{\"question\":\"How was DCAF5 expression measured in renal clear cell carcinoma?\",\"answer\":\"The study used immunohistochemical analysis to compare DCAF5 expression in renal clear cell carcinoma tissues with adjacent non-neoplastic tissues.\"},{\"question\":\"What did the study find about DCAF5 as a prognostic and immunotherapy biomarker?\",\"answer\":\"DCAF5 expression was significantly reduced in tumor tissues, associated with patient outcomes, and correlated with immune scores and immune cell infiltration across multiple cancer types. The findings indicate superior predictive value over traditional biomarkers such as TMB for immunotherapy personalization.\"}]","Identification of DCAF5 as a novel cancer prognostic and immunotherapy biomarker through pan-cancer analysis and renal clear cell carcinoma clinical data validation | PDF",1790171397,48,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b3d81ae53d19fa67ee85aa28fec7a970.webp",983,1310,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9c2e4ff6917dff833eac41de7e196112.webp",982,1309,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/92643d3f4af50bdc91d8d8f3e734d65f.webp",981,1308,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3e2b341e8dd5b698a5ccdab17c6c0954.webp",980,1306]